RxDoctor Payments Data

Cody Reese, PA

Medical · Coeur D Alene, IDNPI 1235521279

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novartis at 27.4% of the total.

$3,150in general payments, 2019–2025

Across 126 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$862
  • Boston Scientific$618
  • Johnson & Johnson$260
  • Abbott$248
  • AstraZeneca$238
  • Amgen$173
  • plus $751 from 10 others

What the payments were for

  • Food & beverage$3,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,150 in reported general payments places this provider in the 85th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$19,029
Medicare patients
191
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$88,257
FarxigaDapagliflozin Propanediol38$27,830
XareltoRivaroxaban32$23,795
EntrestoSacubitril/Valsartan17$14,230
BrilintaTicagrelor20$11,996
Atorvastatin Calcium201$2,476
Metoprolol Succinate225$2,225
ClopidogrelClopidogrel Bisulfate230$2,065
Ezetimibe111$1,846
Rosuvastatin Calcium110$1,293
Losartan Potassium128$993
Amlodipine Besylate78$687
Lisinopril90$579
Nitroglycerin60$549
Carvedilol70$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$88,25785 claims
AstraZenecaFarxiga, Brilinta$238$39,82658 claims
Johnson & JohnsonXarelto$260$23,79532 claims
NovartisEntresto$862$14,23017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 265 medical providers in Idaho.

Other medical in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →